

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
22908-1235BSERIAL NO.  
09/482,682LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
VON SEGGERN et al.FILING DATE  
January 14, 2000GROUP  
1648

\* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
SF	*A	2002	0	0	3	7	8	51	03/28/02	Fleckenstein et al.	514	12	04/16/01
SF	*B	5	1	4	9	7	8	0	09/22/92	Plow et al.	530	324	10/03/88
SF	*C	5	7	5	0	3	9	6	05/12/98	Yang et al.	435	357	05/08/95

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
SF	*D	0	0	4	2	2	0	8	07/20/00	PCT				
	*E	0	1	8	3	7	2	9A2	11/08/01	PCT				
	*F	0	1	9	2	2	9	9A2	12/06/01	PCT				
	*G	9	4	1	7	8	3	2	08/18/94	PCT				
	*H	9	5	0	2	6	9	7	01/26/95	PCT				
	*I	9	5	2	7	0	7	1	10/12/95	PCT				
	*J	9	6	0	7	7	3	4	03/14/96	PCT				
	*K	9	7	2	1	8	2	6	06/19/97	PCT				

X\* = An English language Derwent abstract is provided.

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	*L	Behnam et al., "Stereotactic Delivery of a Recombinant Adenovirus into a C6 Glioma Cell Line in a Rat Brain Tumor Model", <i>Neurosurgery</i> , 35(5):910-916 (1994)
	*M	Caravokyri et al., "Constitutive Episomal Expression of Polypeptide 1X (pIX) in a 293-Based Cell Line Complements the Deficiency of pIX Mutant Adenovirus Type 5", <i>J. Virol.</i> , 69(11):6627-6633 (1995)
SF	*N	Certified English Translation of Tatsumi et al., "Thyroid-Stimulating Hormone (Thyrotropin) (TSH) - From Gene Structure to Expression," <i>Nihon Rinsho</i> 47(10): 2213-2220 (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **ADENOVIRUS VECTORS, PACKAGING CELL LINES, COMPOSITIONS, AND METHODS FOR PREPARATION AND USE**

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
22908-1235BSERIAL NO.  
09/482,682LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
VON SEGGERN et al.FILING DATE  
January 14, 2000GROUP  
1648

\* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

SF	*O	Derwent# 010166087, WPI Acc. No. 1995-067340/199509, citing PCT Patent Application No. WO 9502697, "New defective recombinant adenovirus for gene therapy - contains inverted terminal repeats, encapsidation sequence and heterologous DNA, also cell lines able to complement the virus defect."
	*P	Engelhardt <i>et al.</i> , "Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses", <i>Nature Genetics</i> , 4:27-34 (1993)
	*Q	Guo <i>et al.</i> , "Apoptosis induced by adenovirus-mediated wild-type p53 expression in human pancreatic cancer cells", article in Chinese, <i>Chin. J. Pathol.</i> , 27(3):194-197 (1998)
	*R	Hallenbeck <i>et al.</i> , "A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma", <i>Hum. Gene Ther.</i> , 10:1721-1733 (1999)
	*S	Harrison, Stephen C., Chapter 3, "Principles of Virus Structure", <i>Virol.</i> , 2nd. Ed., pp. 37-61 (1990)
	*T	Kay <i>et al.</i> , "Genetically Targeted Research & Therapeutics: Antisense & Gene Therapy", <i>Cell. Biochem.</i> , 17E:207 S310 (1993)
	*U	Krougliak <i>et al.</i> , "Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants", <i>Hum. Gene Ther.</i> , 6:1575-1586 (1995)
	*V	Legrand <i>et al.</i> , "Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber," <i>J. Virol.</i> 73(2): 907-19 (1999)
	*W	Mittal <i>et al.</i> , "Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter", <i>Virus Res.</i> , 28:67-90 (1993)
	X	Mittereder <i>et al.</i> , "Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy," <i>J. Virol.</i> 70(11): 7498-7509 (1996)
	Y	NCBI Nucleotide J04514
	*Z	NCBI Nucleotide M73260
	*AA	NCBI Nucleotide M12411
	*AB	NCBI Nucleotide M18369
SF	*AC	Nemerow, G.R., "Adenoviral Vectors - new insights", Elsevier Science Ltd., PII:S0968-842X (2000)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **ADENOVIRUS VECTORS, PACKAGING CELL LINES, COMPOSITIONS, AND METHODS FOR PREPARATION AND USE**

RECEIVED  
APR 24 2003  
TECH CENTER 1600/2900

FORM PTO-1449 (Modified)



LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

ATTY. DOCKET NO.  
22908-1235B

SERIAL NO.  
09/482,682

APPLICANT  
VON SEGGERN et al.

FILING DATE  
January 14, 2000

GROUP  
1648

\* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

SF	*AD	Nemerow, NIH Grant HL54352, "Alpha-V Integrins and Adenovirus Cell Entry", funding period from 01/20/95 to 12/31/03
/	*AE	Rich <i>et al.</i> , "Development and Analysis of Recombinant Adenoviruses for Gene Therapy of Cystic Fibrosis", <i>Hum. Gene Ther.</i> , <u>4</u> :461-476 (1993)
/	*AF	Swift <i>et al.</i> , "Tissue-Specific Expression of the Rat Pancreatic Elastase I Gene in Transgenic Mice", <i>Cell</i> , <u>38</u> :630-646 (1984)
/	*AG	Wickham <i>et al.</i> , "Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins," <i>J. Virol.</i> <u>71</u> (11): 8221-9 (1997)
SF	*AH	Yang <i>et al.</i> , "Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy", <i>Proc. Natl. Acad. Sci. USA</i> , <u>91</u> :4407-4411 (1994)

RECEIVED

APR 24 2003

TECH CENTER 1600/2900

EXAMINER

*Sharon Foley*

DATE CONSIDERED

*9/5/03*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **ADENOVIRUS VECTORS, PACKAGING CELL LINES, COMPOSITIONS, AND METHODS FOR PREPARATION AND USE**